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Abbreviations 
A  late diastolic velocity of the transmitral Doppler flow 
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DLCO/VA  Carbone monoxide diffusing capacity adjusted for alveolar volume 
E  Early diastolic velocy of the transmitral Doppler flow 
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FFR   Fractioned Flow Reserve 
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FVC  Forced Vital Capacity 
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hsCRP  high-sensitivity C-Reactive Protein 
IMR  Index of Myocardial Resistance 
IMRbas  basal Index of Myocardium Resistance 
IMRhyp  hyperaemic Index of Myocardium Resistance 
iPAH  idiopathic Pulmonary Arterial Hypertension 
lcSSc   limited cutaneous Systemic Sclerosis 
LV   Left Ventricular 
LVEF   Left Ventricular Ejection Fraction 
MCTD  Mixed Connective Tissue Disease 
mPAP  mean Pulmonary Arterial Pressure 
MRI   Magnetic Resonance Imaging 
MVD  Microvascular Dysfunction 
NO  Nitric oxide 
Pa  Aortic pressure 
PAH   Pulmonary Arterial Hypertension 
PAH-CTD  Connective tissue disease associated Pulmonary Arterial Hypertension 
PAP  Pulmonary Arterial Pressure 
Pd  distal Coronary Pressure 
PH   Pulmonary Hypertension 
PM  Polymyositis 
PVR  Pulmonary Vascular Resistance 
Pw  wedge Pressure 
QCA  Quantitative Coronary Angiography 
RA  Rheumatoid Arthritis 
RHC  Right Heart Catheterization 
RP   Raynaud‘s Phenomenon 
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SD  Standard Deviation 
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SSc   Systemic Sclerosis 
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stent and Cardiac Surgery trial 
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1 Introduction 
1.1 Systemic sclerosis 
Systemic sclerosis (SSc) is a connective tissue disease (CTD) characterized by vascular 
abnormalities and excessive fibrosis. Manifestations of SSc may occur in numerous tissues 
and organs resulting in significant morbidity and mortality
1
. In an individual case variable 
combination of organ damage or, less frequently, a severe, single organ involvement is 
responsible for SSc morbidity and mortality. The functional impairment of different organs 
shows variable, frequently subclinical progression and overlap that makes the long-term 
outcome of SSc extremely unpredictable. The life expectance of SSc patients was 
considerably improved with the introduction of angiotensin-inhibitory treatment that reduced 
the emergence of the scleroderma renal crisis. More recently with the advent of novel 
effective therapies and with regular screening of SSc patients for pulmonary hypertension, its 
impact on mortality has been decreased. Recent cohorts report that the primary cause of death 
in scleroderma is related to pulmonary and cardiac causes. While the overall long-term 
prognosis of patients with SSc seems to have improved in recent years, the proportion of 
deaths due to heart disease has not changed significantly
2
.  
Cardiac manifestations are common in SSc, with an estimated clinical prevalence of 15–35%3, 
4
. In the majority of SSc patients, however, cardiac manifestations may remain subclinical
5, 6
. 
Individuals who develop clinically apparent myocardial manifestations are recognized to be at 
greater risk of clinical deterioration
7
, and monitoring of myocardial involvement represents an 
important aspect of their disease management
8
. 
Cardiac manifestations may affect patients with either lcSSc or dcSSc and, when clinically 
evident, are often associated with increased mortality irrespective of disease subtype
3, 4, 9, 10
. 
Vlachoyiannopoulos et al.
11
 retrospectively analysed the clinical files of 254 patients over 4 
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years. They estimated that the mortality rate is 2% per year, and the incidence of cardiac 
disease is between 7% in lcSSc and 21% in dcSSc patients
11
. Similarly, a review of 1095 SSc 
patients between 1959 and 1988 estimated the overall mortality of SSc to be 33%, with deaths 
of 42 patients (4.5%) resulting from cardiac manifestations
12
. Another review of 405 SSc 
patients followed for 5 years determined that 21 out of 145 (14%) patient deaths were due to 
cardiac manifestations, at a rate of 1% per year
13
.  
1.1.1 Scleroderma Heart Disease 
Cardiac involvement in systemic sclerosis may affect the endocardium, myocardium and 
pericardium, separately or concomitantly. As a consequence, it may result in pericardial 
effusion, arrhythmias, conduction system defects, valvular impairment (in rare cases), 
myocardial ischemia, myocardial hypertrophy and heart failure
8
. Renal and pulmonary 
involvement can also adversely affect cardiac status. 
These primary myocardial manifestations—those without systemic or pulmonary 
hypertension and without significant pulmonary or renal disease—predominantly result from 
the underlying vascular pathology of SSc, i.e. the characteristic vascular lesions and fibrosis 
that impair microcirculation and myocardial function, respectively
8
. The signs of early 
myocardial manifestations of SSc are often non-specific and subclinical. Consequently cases 
with cardiac manifestations may remain undiagnosed, potentially enabling the disease to 
progress silently. This particular progression manifests only as a slowly reducing physical 
capacity, and limiting effort related dyspnoea. Conversely, progressive deterioration of 
cardiac dysfunction with clinically, overt cardiac decompensation may occur in some SSc 
patients. Early diagnosis is therefore very important. Currently several recommendations 
support the regular echocardiographic screening of SSc cases and for patients with SSc 
undergoing autologous haematopoietic stem cell transplantation, a full cardiological 
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assessment before and during the transplant is recommended, as patients with cardiac 
abnormalities are known to be at increased risk of mortality
14
. The presence of ischemia in 
scleroderma heart disease (SHD) is supported by several in vivo studies, using SPECT, 
echocardiography and MRI and post-mortem histologic findings
5, 6, 8, 15, 16
. These results 
suggest the existence of reversible functional and vasospastic abnormalities (demonstrated by 
SPECT, echocardiography and MRI) as well as fixed abnormalities due to fibrosis or organic 
abnormalities of small coronary vessels (demonstrated by post-mortem studies and the 
methods used in vivo)
5, 6, 8, 16
. In a study of 52 consecutive patients with SSc (mean disease 
duration since first non-RP 6.6±6.1years) cardiac abnormalities were observed in 75%. 
Abnormal findings were as common in limited as in diffuse disease. Thinning of the left 
ventricular myocardium was found in 29% of the patients and pericardial effusion and systolic 
and diastolic ventricular dysfunction were also common.
17
 A multicenter study of SSc showed 
a 5.4% prevalence of LV dysfunction and identified age, male gender, myositis, digital ulcers, 
lung involvement and absence of previous treatment with calcium channel blockers as 
predictors of reduced left ventricular ejection fraction (LVEF)
18
. Right ventricular dilation 
was noted in seven patients in whom pulmonary hypertension was excluded by 
catheterization. Myocardial fibrosis in a non-coronary distribution was found in 21% of the 
patients
16
. 
1.1.1.1 Abnormalities in cardiac microcirculation 
Numerous abnormalities in the cardiac microcirculation may affect patients with SSc. 
Alterations of the microvasculature and microvascular dysfunction (MVD) may play a crucial 
role in the development of SHD
19
. Observations suggest that coronary flow reserve (CFR) is 
reduced in SSc. Kahan et al. measured first invasively the coronary sinus blood flow, and 
described that some patients had markedly reduced coronary vasodilatory response despite the 
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lack of atherosclerotic coronary artery disease (CAD)
20, 21
. This observation has been 
confirmed with several alternative methodologies. 
Vasospasm of the small coronary arteries and arterioles is a major, important and early 
cardiac manifestation that can be observed at rest or induced in both symptomatic and 
asymptomatic SSc patients following cold pressor testing
22
. Interestingly, this type of 
microvascular ischemia has been investigated in other rheumatic diseases associated with 
Raynaud phenomenon (RP), but has not been detected in those cases
23
. 
One abnormality of the myocardial microcirculation that is typically exhibited late in patients 
with SSc is reduced coronary flow reserve, which is believed to result from fixed, structural 
abnormalities of the small coronary arteries and arterioles. This has been investigated in 
patients with dcSSc with established myocardial involvement and normal coronary 
arteriograms
21
. These patients were not different to controls at baseline, but exhibited 
strikingly reduced vasodilator reserve following maximal coronary vasodilation with 
intravenous dipyridamole
21
. Thallium-201 SPECT and MRI enable abnormalities in cardiac 
perfusion to be investigated in greater detail
24
. Studies using these techniques have 
demonstrated that SSc patients may benefit from the administration of the calcium channel 
blockers nifedipine
6, 25-27
, the angiotensine-converting enzyme (ACE) inhibitor captopril, as 
well as intravenous dipyridamole used as a pharmacodynamic test inducing maximal coronary 
artery vasodilatation
25
. Treatment of SSc patients with these agents has been observed to 
improve myocardial perfusion; however, not all abnormalities in myocardial perfusion are 
reversible. It is possible that ischemic lesions amenable to vasodilator therapy may co-exist 
with irreversible lesions, such as those with organic abnormalities or associated with fibrosis
8
. 
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Several studies have attempted to characterize the coronary vasoreactivity in SSc patients 
using non-invasive methods
28-30
. Measurement of the diastolic coronary flow obtained by 
transthoracic echocardiography initially has been reported to exhibit suboptimal feasibility, 
which can be improved by using contrast augmentation of the Doppler signal and second 
harmonic technology (CFRecho)
31-33
. Sulli et al. found significantly lower CFRecho values 
among patients with diffuse SSc than in subjects suffering from the limited form of the 
disease. Furthermore, CFRecho values in SSc differed significantly from healthy controls
30
. 
Montisci et al recently reported beneficial effect of single intravenous administration of L-
propionylcarnitine to the CFRecho. The authors noted that the peak diastolic velocity was 
significantly decreased in the left anterior descending coronary artery in basal conditions and 
the CFRecho measured during adenosine infusion increased significantly after the L-
propionylcarnitine application.  They explained that the decreased resting coronary flow 
velocity may be the result of the ―anti-endothelin‖ effect of L-propionylcarnitine for 
microvascular tone and this agent could cause improved sensitivity for adenosine infusion
31
. 
D‘Andrea et al analyzed the supposed correlation among left ventricular (LV) function, CFR 
examined by echocardiography and endothelial function investigated by flow mediated 
dilatation method. The authors conclude that endothelial dysfunction in SSc patients was not 
confined to coronary microvessels, but also extends to peripheral arteries
28
. Similar results 
were found earlier by Andersen et al
34
. 
1.1.1.2 Abnormalities in myocardial tissue 
Myocardial fibrosis is a hallmark cardiac manifestation of SSc that can remain subclinical for 
a considerable period of time
8
. The fibrotic lesions are patchy, distributed in both ventricles 
and are inconsistent with regards to coronary artery distribution. Myocardial fibrosis occurs 
later in SSc and can lead to systolic and diastolic dysfunction, including exercise-induced 
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dysfunction, segmental dysfunction, decreased peak filling rate and reduced global left and 
right ventricular ejection fractions
12
. Myocardial fibrosis in SSc can affect both ventricles, 
leading to increased ventricular mass, decreased movement of the ventricular walls and 
impaired relaxation of myocardial tissue during diastole
9, 35
. The combined effects of 
myocardial fibrosis and reduced perfusion can be investigated using tissue Doppler 
echocardiography (TDE), which enables sensitive and non-invasive measurement of 
myocardial contractility. Using this technique, myocardial contractile velocities and strain 
rates in SSc patients have been found to be reduced, although the exact pathological 
mechanism underlying such reductions remains unclear
8
. Vignaux et al.
27
 investigated the 
effects of nifedipine in 18 SSc patients with reduced systolic and diastolic contractile strain 
rates. In these patients, nifedipine significantly improved MRI perfusion index, and the 
systolic and diastolic TDE strain rates
27
. Further investigations to evaluate the effects of 
nifedipine in a greater number of patients with cardiac manifestations of SSc are, however, 
necessary. Short-term treatment with the dual endothelin receptor antagonist bosentan has 
been evaluated in 18 SSc patients without clinical heart failure and with normal pulmonary 
arterial pressure
36
. Short-term treatment with bosentan simultaneously improved myocardial 
perfusion and function. It remains to be seen if long-term treatment might result in additional 
remodelling effects. 
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1.2 The coronary circulation 
1.2.1 The arterial system 
The arterial tree consists of large arteries ranging from several mm to 400µm and branching 
into small arteries and arterioles (with a diameter 400µm). The arterioles are surrounded by 
smooth muscle cells. The distinction between large and smaller arteries is not sharp; it 
corresponds to physiological and clinical differences. 
The epicardial vessels can be the sites of atherosclerotic narrowings which are the main cause 
of the myocardial ischemia. Normal epicardial arteries do not create any significant resistance 
to blood flow. Even at high flow rates induced by intravenous adenosine, only a negligible 
pressure difference exist between central aorta and the most distal part of epicardial 
coronaries, therefore these are called conductance vessels
37
. The arterioles called as resistance 
vessels are able to dilate under physiological and pharmacological stress. This modulation of 
resistance is paramount for matching myocardial blood flow to variable energy requirements. 
The ability to dilate may be impaired before the development of visible atherosclerosis.
38-40
 
This two-compartment model of the coronary circulation does not account for the 
heterogeneity in the distribution of coronary resistance with respect to regulation of coronary 
blood flow
41
. Based on sequential differences in the response to shear stress and adenosine, 
resistance vessels have been divided into two groups:  
The proximal compartment consists of vessels with a diameter ranging from 100-400 µm. 
Their tone is controlled by coronary flow, distending pressure and myogenic tone, and 
modulated by the autonomic nervous system and endothelial function. 
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The distal compartment consists of vessels with a diameter of less than 100 µm and 
influenced primarily by the perfusion pressure and by myocardial metabolism. 
1.2.2 Capillaries 
The diameter of the capillaries is approximately 5 µm; their density is 3500-4000/mm2 in 
human heart. The myocytes are connected to the capillary wall by collagen struts. Each 
myocyte is lined by at least one capillary in close anatomic structure. Capillaries are not 
uniformly patent because precapillary sphincters regulate flow according to oxygen demand.  
1.2.3 Coronary flow characteristic, regulation of myocardial blood flow 
The coronary arterial blood flow occurs predominantly during diastole. The myocardial 
perfusion represents approximately 5% of cardiac output under baseline conditions. In case of 
normal epicardial coronary arteries, coronary flow equals myocardial flow. The myocardial 
oxygen demand is high (8-10 ml/min/100 g of tissue) as compared to skeletal muscles (0.5 
ml/min/100g)
42
.The high density of coronary capillaries is optimally suited to meet high 
oxygen consumption. The extraction of oxygen by the myocardium is close to maximum.  
Hence, since oxygen extraction cannot increase much further, the coronary circulation can 
only meet increasing oxygen demand by increasing blood flow, so there is a close linear 
relation between the metabolic demand and myocardial blood flow
43
. The flow is regulated by 
a changing balance of interacting mechanisms, including intrinsic autoregulation, external 
compressive forces, neural regulation, metabolic demand and endothelial factors. 
1.2.3.1   Autoregulation 
Myocardial perfusion is maintained relatively constant when perfusion pressure varies from 
45 to 130 mmHg approximately in humans
44
. When coronary perfusion pressure falls below 
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this limit, small additional reductions in pressure are associated with marked reduction in 
myocardial flow and wall thickening. Despite mild or moderate epicardial stenoses, coronary 
blood flow is maintained by compensatory vasodilatory regulation of the microcirculation 
(autoregulation). 
The main supposed mechanism is the local metabolic regulation. Several metabolic mediators 
have been studied, e.g. oxygen, CO2, hyperosmolarity, H
+
, K
+
, and Ca
++
 concentration, 
adenosine and nitric oxide (NO). 
1.2.4 Coronary reserve  
Coronary vasodilator reserve is the ability of the coronary vascular bed to increase flow above 
the basal level in response to a mechanical or pharmacological stimulus (e.g. reactive 
hyperemia, exercise, pharmacologic agents), to a maximal hyperemic level. 
1.2.4.1 Fractional flow reserve (FFR) 
Fractional flow reserve is an index specific for the degree of epicardial coronary artery 
stenosis. FFR is calculated as a ratio of distal and aortic pressure during hyperemia.  FFR 
measurements demonstrated no significant variation during various hemodynamic conditions 
in a recent study
45
.  
1.2.4.2 Coronary flow reserve (CFR) 
Coronary flow reserve is expressed as the ratio of maximal hyperemic flow to resting 
coronary flow – a ratio that averages from 2 to 5 in humans46, 47. 
The feasibility of CFR to reflect the functional state of the microcirculation independently is 
limited because CFR is influenced by the flow status of both the epicardial artery and the 
microcirculation hence does not allow discrimination between these two components
48
. 
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Furthermore, CFR is limited by its dependence on heart rate and blood pressure, therefore its 
reproducibility seems to be questionable. 
Currently used devices, such as the pressure-temperature sensor-tipped coronary wires allow 
to measure pressure and to estimate coronary artery flow simultaneously
49
. Based on 
thermodilution principles, the mean transit time (Tmn) of room-temperature saline injected 
down a coronary artery can be determined and has been shown to correlate inversely with 
absolute flow
49
. Use of CFR to evaluate the microcirculation is limited by the fact that CFR 
interrogates the entire coronary system, including the epicardial artery and the 
microcirculation
50
. For this reason, a patient with epicardial disease but with normal 
microcirculatory function can have an abnormal CFR, which potentially limits the 
applicability of CFR when assessing microvascular disease. Furthermore, because CFR 
represents a ratio between peak hyperemic and resting coronary flow, factors that affect 
resting hemodynamics, such as heart rate and contractility, may affect the reproducibility of 
CFR
51
. Previous studies have shown that Doppler flow velocity– derived CFR is significantly 
reduced by tachycardia
51-53
 and by increased contractility but is not significantly affected by 
changes in blood pressure due to compensatory changes in coronary blood flow
51-53
. 
Consistent with these previous studies, study of Ng et al. documented the hemodynamic 
dependence of thermodilution-derived CFR. In this study, hypotension induced by 
nitroprusside infusion had no effect on thermodilution-derived CFR. In contrast, right 
ventricular pacing–induced tachycardia and dobutamine infusion were both associated with 
significant reductions in thermodilution-derived CFR values, largely due to an increase in 
resting coronary blood flow (and hence a reduction in resting Tmn)
45
. 
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1.2.5 Index of myocardial resistance 
In normal coronary vessels there is a big difference in resistance between baseline and 
hyperemia in the arterioles. These vessels have an ability to adjust, relax and contract their 
tone in response to wide range of stimuli. Contrary, there is no significant difference 
regarding the resistance between rest and hyperemia in the large epicardial vessels and in the 
small capillaries. At hyperemia the capillaries offer the highest resistance. Conditions 
associated with lesser capillaries, such as myocardial infarction, hypertension and diabetes, 
are associated with reduced blood flow despite the absence of coronary stenosis. 
Myocardial resistance equals the pressure drop across the myocardium, divided by the 
myocardial blood flow during hyperemia. Assuming venous pressure close to zero, the 
pressure drop equals distal coronary pressure (Pd). Using the thermo-dilution principle, blood 
flow equals 1/Tmn then IMR = Pd x Tmn, at maximal hyperemia. 
Mean transit time (Tmn) can be measured by injecting saline into the coronary artery and it is 
inversely proportional to coronary blood flow. This simplified formula assumes that the 
coronary flow is identical to myocardial flow. In the presence of a severe stenosis this 
assumption is not correct, since collateral flow will increase, and IMR will be overestimated 
using this formula. To compensate for the collateral flow, wedge pressure (Pw), must be 
incorporated into the formula
54
: 
IMR = Pd x Tmn x FFRcor / FFRmyo  
IMR = Tmn x Pa x (Pd-Pw) / (Pa-Pw) 
Pa = Aortic Pressure, Pw = Wedge Pressure (distal pressure under total occlusion), Pd = Distal Pressure 
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If collateral flow (wedge pressure) is not accounted for, IMR increases with increasing 
stenosis severity. By measuring wedge pressure and incorporating this in the calculation, IMR 
remains fairly constant even with increasing stenosis severity. IMR has significantly lower 
variation as compared to CFR after changes in pressure, heart rate and contractility.  
The state of the coronary microcirculation is an important determinant of patient outcomes in 
a number of clinical settings, including acute coronary syndromes, percutaneous coronary 
interventions, and other microcirculatory perturbations. The index of myocardium resistance 
(IMR) has been shown in animals to correlate with true microvascular resistance and, unlike 
coronary flow reserve (CFR), to be independent of the epicardial artery
55
. In animal model, 
IMR, defined as the distal coronary pressure divided by the inverse of the hyperemic mean 
transit time, correlated well with an accepted experimental method for measuring 
microvascular resistance
55
. 
Unlike CFR, IMR is derived at peak hyperemia, thereby eliminating the variability of resting 
vascular tone and hemodynamics. Ng et al. evaluated the intrinsic variability of CFR and IMR 
under baseline conditions and after a series of hemodynamic interventions that included right 
ventricular pacing at 110 bpm, nitroprusside infusion, and dobutamine infusion. In the resting 
state, heart rate, mean coronary transit times, and systemic and distal coronary pressures were 
similar between the two baseline measurements. They compared the IMR with 
thermodilution-derived CFR in terms of reproducibility and dependence on hemodynamic 
changes and also concurrently measured FFR under different hemodynamic conditions. The 
salient findings of the present study were as follows: (1) IMR demonstrates less intrinsic 
variability and better reproducibility at baseline than CFR, and (2) whereas CFR is very 
sensitive to hemodynamic changes, IMR is largely independent of variations in hemodynamic 
state. Furthermore, FFR (when simultaneously measured with IMR and CFR) is highly 
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reproducible and also largely independent of hemodynamic state. These findings suggest that 
IMR could be reliably applied in the catheterization laboratory for assessment of 
microcirculatory resistance. Furthermore, simultaneous measurement of FFR and IMR with a 
single pressure-temperature sensor-tipped coronary wire may provide a simple means for 
comprehensive and specific assessment of coronary physiology at both epicardial and 
microvascular levels, respectively
45
.  
In a recent study using a porcine animal model, Ng et al. found that IMR distinguished 
between normal and abnormal microcirculatory function and correlated well with true 
microcirculatory resistance as measured by an external flow probe and pressure wire
55
. 
Furthermore, IMR, in its simplest form, was not significantly affected by the presence of a 
moderate to severe epicardial stenosis and is therefore a specific measure of the state of the 
microcirculation, unlike CFR. In more severe stenoses, in which collateral flow may be 
contributing to myocardial perfusion, a more complex form of IMR, which incorporates the 
coronary wedge pressure, is necessary to accurately determine microvascular resistance
50, 54
. 
Variations in hemodynamic status, including changes in heart rate, blood pressure, and 
contractility, do not significantly affect IMR measurements. During all hemodynamic 
interventions in the present study (rapid right ventricular pacing, nitroprusside infusion, and 
dobutamine infusion), IMR exhibited greater hemodynamic stability than CFR
45
. 
1.3 Pulmonary hypertension 
Pulmonary arterial hypertension (PAH), a disease of the pulmonary circulation, is defined as a 
mean pulmonary arterial pressure (mPAP) of> 25mmHg at rest or> 30mmHg during exercise 
together with a pulmonary capillary wedge pressure of <15mmHg
56
. Sustained increases in 
PAP result in an increase in pulmonary vascular resistance (PVR), which in turn leads to right 
ventricular overload, and ultimately right ventricular failure and death
57
. Irrespective of its 
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underlying cause, the elevations in PAP that characterize PAH are believed to occur at least in 
part from disturbances in the normal balance between endogenous vasoconstrictors and 
vasodilators in response to endothelial dysfunction or injury
58
. Simultaneously in the 
vasculature, there is increased production of potent vasoconstrictors such as thromboxane A2 
and ET-1 and reduced production of vasodilators such as nitric oxide (NO) and prostacyclin 
synthase, which is required to convert arachidonic acid to prostacyclin. These abnormalities 
elevate vascular tone and promote remodelling of the vascular wall, which leads to the 
persistent increase in PVR and its adverse clinical sequelae
59
. PAH is a devastating and often 
fatal complication of CTDs, especially within the scleroderma (SSc) patient population, which 
has the highest mortality of all the rheumatic disorders
60
.  
1.3.1 Classification of pulmonary hypertension  
An increased understanding of the pathophysiology of PAH has enabled important advances 
in the classification of pulmonary hypertension (PH). This classification has progressed from 
its initial separation into primary and secondary PH, via the Evian classification of 1998
61
, to 
today‘s Venice classification. The Venice classification, which arose from the 2003 Third 
World Symposium on PAH
57
, recognizes five subclasses of chronic PH. Recent modification 
of this is the Dana Point Classification that was published in 2009, maintained the main 
pathogenesis based structure of the earlier versions and included the latest research results. 
The first of these main groups is the pulmonary arterial hypertension (PAH) that is frequently 
encountered in patients with SSc. The second category is pulmonary venous hypertension, in 
which increased PAP arises from elevated pressures on the left side of the heart. Anything 
that elevates left heart filling pressures, left ventricular end-diastolic pressure or wedge 
pressure is transmitted back to the pulmonary vasculature and can cause PH. Potential 
contributors to this type of PH include systolic dysfunction, diastolic dysfunction, which is 
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not uncommon in SSc patients, and valvular heart disease such as aortic valve disease or 
mitral valve disease. Because the treatment of PH associated with left heart disease is very 
different to that for PAH, it is important to differentiate this form of PH from PAH. The third 
type of PH is associated with hypoxemia and lung disease. Anything that causes hypoxemia 
can lead to modest increases in mPAP to 25–35 mmHg, whereas any type of lung disease, 
such as interstitial lung disease and pulmonary fibrosis, which are common in patients with 
SSc, and sleep apnoea can also cause this type of PH. Chronic thromboembolic PH (CTEPH), 
which is thought to develop from single or recurrent thromboembolism at sites of venous 
thrombosis that fail to be reabsorbed, represents the fourth category of PH. Again, it is very 
important to differentiate CTEPH from PAH as CTEPH patients with proximal, surgically 
accessible disease may be cured with pulmonary endarterectomy. Finally, the Venice 
classification recognizes a fifth subclass of chronic PH that includes sarcoidosis and some 
unusual diseases that affect the pulmonary vasculature directly
62
. 
1.3.2 PAH associated with CTDs 
The vascular remodelling that occurs in PAH arises from the extension of muscle into 
peripheral non-muscular arteries following the differentiation of pericytes and intermediate 
cells into mature smooth muscle cells
59
. In normally muscular arteries, medial hypertrophy 
develops as a result of cellular hypertrophy/hyperplasia accompanied by extracellular matrix 
deposition. Loss or impaired growth of arterioles may also occur and, as the disease 
progresses, plexiform lesions, fibrosis and in situ thrombosis may develop. Thus, there are 
three main events in the pathophysiology of PAH: vasoconstriction, thrombosis and most 
importantly remodelling. PAH is a significant and often fatal complication of CTDs, 
including not only SSc but also SLE, MCTD and, to a lesser extent primary SS, PM and 
RA
14
. Data from the French National Registry of 674 patients with PAH show that 95% of all 
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the cases of PAH-CTD are associated with SSc (76%), SLE (15%) or MCTD
63
. Thus, PAH is 
a rare complication in patients with RA, SS and PM. Within the SSc patient population, 
prevalence of confirmed PAH is ~10–16%14. This is a finding borne out by Wigley‘s recent 
surveys
64
. Data from the French National Registry show that about two-thirds of the cases of 
PAH-SSc are patients with limited SSc and a third of cases are patients with diffuse SSc
63
. 
PAH is a leading cause of disease-related death in SSc patients
65
, in whom outcome has 
historically been much worse than in patients with iPAH
66
. With median survival of just 1 
year, the survival rate for patients with PAH-SSc on conventional therapy is poor
67
. 
Diagnosis of PAH in this patient group is difficult as clinical symptoms and findings 
considerably overlap with several other internal organ involvements.  
1.3.3 Diagnostic approach to patients with suspected PAH 
Assessment of PAH is based on a logical sequence of determining whether there is a risk of 
PAH being present, whether PAH is likely to be present based on initial, noninvasive 
evaluation, clarifying the underlying etiology of PAH in an individual patient, and delineating 
the specific hemodynamic profile, including the acute response to vasodilator testing. Risk 
groups warranted to screen for PH include the following: patients with known genetic 
mutations predisposing to PH, first-degree relatives in FPAH family, patients with 
scleroderma spectrum of disease, patients with portal hypertension prior to liver 
transplantation, and patients with congenital heart disease with systemic-to-pulmonary shunts. 
Patients with PAH generally present with a spectrum of symptoms attributable to impaired 
oxygen transport and reduced cardiac output. Although PAH may be asymptomatic, 
particularly in its early stages, exertional dyspnoea is the most frequent presenting symptom. 
Dyspnoea is eventually present in virtually all patients as the disease progresses. Fatigue, 
weakness, or complaints of general exertion intolerance are also common complaints. As 
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PAH progresses, dyspnoea may be present at rest. Chest pain and syncope are each reported 
by approximately 40% of patients during the course of the disease. Since the symptoms of PH 
are nonspecific, the initial evaluation of patients with these symptoms is often appropriately 
directed at diagnosing or excluding more common conditions.  
Signs of PH on physical examination are subtle and often overlooked. Although no rigorous 
analysis of the sensitivity and specificity of findings on physical examination has been 
performed, experience suggests that the likelihood of PAH is increased when certain findings 
are present. PAH results in right ventricular hypertrophy and right-heart dilation. Since these 
processes produce ECG abnormalities, the ECG may provide a signal of hemodynamically 
significant PH.  
Echocardiography with Doppler ultrasound is the most portable and widely available 
technology among the noninvasive imaging methods. Echocardiography provides both 
estimates of pulmonary artery pressure and an assessment of cardiac structure and function. 
These features justify its application as the most commonly used screening tool in patients 
with suspected PAH. 
Although Doppler echocardiographic methodology may provide a proxy measurement of 
pulmonary hemodynamics by estimating right ventricular pressure, a more accurate value for 
pulmonary artery pressure obtained by right-heart catheterization is strongly advised. Right-
heart catheterization also provides direct and accurate measurements of RAP, pulmonary 
venous pressure (pulmonary capillary wedge pressure), pulmonary blood flow, mixed venous 
oxygen saturation, and allows for the calculation of pulmonary vascular resistance. Right-
heart catheterization not only provides important indices of disease severity, but it also 
enhances the diagnostic process by excluding other etiologies such as intracardiac or 
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extracardiac shunts and left-heart disease, and provides an assessment of the degree of right-
heart dysfunction through measurement of RAP and cardiac output. It should be 
acknowledged that right-heart catheterization also has limitations: measurements are generally 
obtained only under resting conditions in the supine position, which may not be representative 
of hemodynamic responses to upright posture, activity, or sleep. Even under these static 
circumstances, measurements may vary
62, 68
. 
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2 Aims 
The cardiac and pulmonary manifestations represent an important diagnostic challenge and a 
huge prognostic burden in patients with systemic slcerosis. Our goal was to design and 
execute a prospective screening program for SSc patients that included classical, non invasive 
screening investigations as well as invasive methods for characterization of cardiopulmonary 
circulatory parameters among high risk cases. We aimed  
 to estimate the prevalence of pulmonary hypertension, atherosclerotic coronary artery 
disease and microvascular dysfunction among SSc patients 
 to characterise the proportion and distribution of these alterations behind the 
overlapping symptoms 
 to investigate the mechanisms of the microvascular impairment by means of analyzing 
the myocardial resistance of SSc patients compared to patients with angina pectoris 
having mild coronary artery disease 
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3 Cross-sectional study of SSc patient for elucidation of the 
prevalence of cardiopulmonary involvement 
3.1 Patients and methods 
A total of 120 consecutive SSc cases were enrolled in the study. SSc was diagnosed by 
standard criteria
1
, and the patients were asked to provide informed consent before the entry. 
Those with an ejection fraction 30% on echocardiography or with known severe valvular 
disease were excluded. Patients with severe lung fibrosis (forced vital capacity 50% on a 
pulmonary function test) were also excluded from further studies (pulmonary fibrosis group). 
Each patient underwent a baseline physical examination. In addition, electrocardiogram, 
echocardiography and a 6-min walk test were also performed. Lung involvement was 
investigated by using chest X- ray, pulmonary function tests and high-resolution CT in cases 
where interstitial lung disease was suspected. Cardiac catheterisation was initiated in the 
presence of abnormalities suggestive of PAH (‗‗suspected PAH‘‘ group) or suggestive of 
CAD (‗‗suspected CAD‘‘ group). Criteria for the ‗‗suspected PAH‘‘ included signs of right 
ventricular involvement on echocardiography; tricuspidal insufficiency diagnosed by flow 
velocity over 3 m/s, or consistent with 2.5–3 m/s in the presence of unexplained dyspnoea; 
signs of right ventricular hypertrophy/dilatation, or right ventricular D sign; and effort related 
dyspnoea with disproportional decrease of CO diffusion capacity (DLCO) compared to the 
forced vital capacity (FVC/DLCO 1.8). Patients were included in the ‗‗suspected CAD‘‘ 
group if they reported recent deterioration in physical activity, evolving effort dyspnoea or 
evolving chest pain, if they fulfilled the criteria of the New York Heart Association functional 
class III–IV, or if their 6-min walking distance was 380 m, but did not fulfilled the criteria 
for PAH
14
. Right heart catheterisation (RHC) and coronary angiography, supplemented with 
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thermodilution coronary flow reserve (CFR) assessment, were performed at the same time. 
The trial protocol was approved by the Medical Research Council Scientific and Ethical 
Committee. 
3.1.1 Echocardiography 
Echocardiography was performed on every patient using Aloka ProSound 5500 ultrasound 
equipment. Ejection fraction was measured by biplane Simpson‘s method. Peak of the early 
(E) and late (A) velocities of the transmitral Doppler flow were measured from the apical 4-
chamber view. Systolic pulmonary artery pressure was estimated by using the simplified 
Bernoulli equation, and calculated from the peak tricuspidal regurgitation velocity (4v
2
 plus 
estimated right atrial pressure according to the diameter and collapse index of the inferior 
vena cava). 
3.1.2 Right heart catheterization 
A Swan-Ganz catheter (B. Braun, Melsungen, Germany) was introduced into a main 
pulmonary artery branch. If the resting mean pulmonary pressure (mPAP) was lower than 30 
mmHg, a 3-minute bench-fly physical stress test was performed with 1kg dumbbells. Mean 
PAP was measured at rest, and at peak exercise. mPAP values of 25 mmHg at rest or 30 
mmHg upon exertion were considered abnormal. 
3.1.3 Coronary angiography 
Angiograms were recorded digitally (Philips Integris, Amsterdam, The Netherlands). 
Coronary lesions were assessed by visual estimation as well as with quantitative angiography 
(QCA). The SYNTAX score, a validated comprehensive angiographic scoring system, was 
used to describe the extent of the CAD
69
. The target artery was instrumented with an 
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intracoronary pressure wire (RADI Medical, Uppsala, Sweden). After baseline measurements 
of aortic pressure (Pa), distal coronary pressure (Pd) and mean transit time of a room 
temperature 3 ml bolus of saline, measurements were performed in triplicate in the presence 
of maximal hyperaemia induced by intracoronary papaverine (12 mg bolus). Fractional flow 
reserve (FFR) was calculated as Pd/Pa ratio during hyperaemia. CFR was calculated from the 
ratio of the mean transit times in hyperaemia and at rest. MVD was defined as reduced flow 
reserve (CFR 2) in the absence of significant stenosis (FFR 0.75). Coronary flow velocity 
was assessed by the ‗‗Thrombolysis in Myocardial Infarction (TIMI) frame count‘‘ (i.e., 
counting the cine frames required for contrast to leave the catheter tip and to reach 
standardised distal landmarks in the coronaries). TFC was measured off-line using a frame 
counter on a digital DICOM viewer (Inturis Suite ViewerLite v1.0, Philips, Holland) by a 
single observer who was blinded to clinical diagnosis. 
3.1.4 Statistical analysis 
For the in-group comparisons, unpaired t tests, x
2
 tests, or Fisher exact tests were used. 
Correlation analysis was performed with the Pearson rho test. 
3.2 Results 
Of the 120 cases, 2 patients were excluded due to severe pulmonary fibrosis. Characteristics 
of the patients are depicted in table 1a, 1b. 
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Systemic 
sclerosis 
(n=120) 
Patients with 
suspected PAH 
(n=20) 
Patients with 
suspected 
CAD (n=10) 
Non 
catheterized 
patients (n=90) 
Antibodies:     
Anti-centromere antibody 24 (20%) 6 (30.0%) 2 (20.0%) 16 (17.8%) 
Anti Scl-70 antibody 43 (35.8%) 5 (25.0%) 3 (30.0%) 35 (38.9%) 
Biochemical data:     
Blood sedimentation (mm/h) 24.6±19.5 28.5±20.0 20.8±19.5 24.2±19.5 
hsCRP (mg/l) 
(norm.: <5mg/l)  
10.4±15.4 9.6±10.6 11.9±15.2 10.4±16.4 
hemoglobin (g/l) 
(norm.:120-170g/l) 
126.9±12.5 127.9±11.7 130.8±13.7 126.2±12.6 
lactate-dehydrogenase (U/l) 
(norm.:<450 U/l) 
339.3±81.2 341.8±108.3 339.8±68.6 338.7±76.8 
creatinine (µmol/l) 
(norm.: 44-80 µmol/l) 
83.8±63.1 81.8±26.5 73.6±12.0 85.4±71.7 
Table 1a: Patient characteristics of the 120 systemic sclerosis patients included in the study. 
Abbreviations: PAH: pulmonary arterial hypertension, CAD: coronary artery disease, hsCRP: high-
sensitivity C-reactive protein. 
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Systemic 
sclerosis 
(n=120) 
Patients with 
suspected PAH 
(n=20) 
Patients with 
suspected 
CAD (n=10) 
Non 
catheterized 
patients (n=90) 
Treatment history:     
Cyclophosphamide 24 (21.7%) 3 (15.0%) 3 (30.0%) 18 (20.0%) 
Low dose corticosteroid 23 (19.2%) 4 (20.0%) 2 (20.0%) 17 (18.9%) 
Pentoxyphilline 116 (96.7%) 19 (95.0%) 9 (90.0%) 88 (97.8%) 
Ca-channel blocker 78 (65.0%) 15 (75.0%) 9 (90.0%) 54 (60.0%)* 
ACE inhibitor 48 (40.0%) 7 (35.0%) 5 (50.0%) 36 (40.0%) 
Spironolactone 42 (35.0%) 10 (50.0%) 8 (80.0%)* 24 (26.7%)* 
H2 blocker and/or proton-pump 
inhibitor 
101 (84.2%) 16 (80.0%) 8 (80.0%) 77 (85.6%) 
Pulmonary status:     
Pleuritis (in case history) 5 (4.2%) 0 (0.0%) 1 (10.0%) 4 (4.4%) 
Pulmonary fibrosis 
(X Ray. diffuse) 
8 (6.7%) 2 (11.1%) 1 (10.0%) 6 (6.7%) 
Pulmonary fibrosis (HRCT) 75 (62.5%) 11 (55.0%) 8 (80.0%) 56 (62.2%) 
Pulmonary fibrosis 
(HRCT diffuse) 
18 (15.0%) 2 (10.0%) 3 (30.0%) 13 (14.4%) 
Forced vital capacity (FVC) 96.2±19.3 94.7±15.4 92.5±20.5 97.0±20.0 
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CO diffusion capacity (DLCO) 63.5±17.8 55.1±18.8 60.5±16.8 65.7±17.2* 
DLCO calculated to alveolar 
volume (DLCO/VA) 
78.0±17.8 71.6±27.1* 78.9±10.4 79.4±15.6 
FVC/DLCO 1.6±0.6 2.1±1.2* 1.6±0.2 1.5±0.4* 
Echocardiography:     
Ejection fraction 61.2±6.4 62.0±6.8 60.8±3.8 61.3±6.9 
Diastolic function abnormality 95 (79.2%) 20 (100.0%)* 9 (90.0%) 66 (73.3%)* 
Calculated RV systolic pressure 
(mmHg) 
30.8±6.2 38.8±7.6** 32.1±6.8 29.9±5.1* 
Table 1b: Patient characteristics, lung function and echocardiographic findings of the 120 systemic 
sclerosis patients included in the study. Abbreviations: PAH: pulmonary arterial hypertension, CAD: 
coronary artery disease, ACE: angiotensin converting enzyme, HRCT: high resolution computer 
tomography, RV: right ventricle, *: p<0.05 **p<0.001 unpaired t test or Fisher’s exact test as appropriate. 
Cyclophosphamide intake was encoded when cyclophosphamide treatment for at least 12 months, with an 
average dose of 1000 mg/month, was recorded in the patient’s medical history. Steroid intake was marked 
when low or medium dose corticosteroid treatment was recorded in the patient’s medical history for at 
least 12 months. 
 
Concerning the cardiovascular risk profile, hypertension and diabetes were more frequent in 
the ‗‗suspected PAH‘‘ group, whereas the distribution of hypercholesterolemia, male gender 
and obesity were similar among groups. No significant difference was detected in any other 
laboratory results. Further details are included in the table 2a, b. 
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All patients 
(n=30) 
Pulmonary 
hypertension 
(PAH) (n=14) 
Coronary 
stenosis (CAD) 
(n=15) 
Microvascular 
disease (MVD) 
(n=10) 
Age (years) 59.5±11.2 62.4±12.1 62.6±10.7* 61.2±13.6 
Echocardiography:     
Ejection fraction 60.8±3.4 60.1±3.6 60.6±3.4 60.4±3.5 
Left ventricular mass (LVM) 191.6±36.5 199.8±25.8 197.9±32.9 184.7±43.8 
E/A 1.0±0.3 0.9±0.3 0.9±0.3 0.9±0.2 
Lung function:     
FVC 93.9±17.0 101.4±12.7* 97.4±15.5 99.4±12.3 
DLCO 56.9±18.0 48.9±13.2* 55.9±17.4 53.6±22.3 
DLCO/VA 74.0±23.0 64.5±19.7* 70.1±19.4 63.5±22.7 
HRCT (performed in 22 out of 
the 30 cases) 
    
Basal fibrosis 18 (60.0%) 8 (57.1%) 8 (53.3%) 6 (60.0%) 
Diffuse fibrosis 5 (16.7%) 1 (7.1%) 3 (20.0%) 2 (20.0%) 
Honeycombing 3 (10.0%) 1 (7.1%) 1 (6.7%) 0 (0%) 
Table 2a: Findings of non-invasive investigations in 30 patients. Abbreviations: E/A: ratio of the early (E) 
and late (A) velocities of the transmitral flow, FVC: forced vital capacity, DLCO: diffusing capacity for 
carbon monoxide, DLCO/VA: carbon monoxide diffusing capacity adjusted for alveolar volume, *: p<0.05 
compared to the rest of the catheterized cases using Fisher’s exact or unpaired t-test as appropriate. 
 
33 
 
 
All patients 
(n=30) 
Pulmonary 
hypertension 
(PAH) (n=14) 
Coronary 
stenosis (CAD) 
(n=15) 
Microvascular 
disease (MVD) 
(n=10) 
Basic hemodynamics:     
Systolic pressure (mmHg) 144.7±24.7 154.3±23.3* 145.9±27.7 146.6±28.6 
Diastolic pressure (mmHg) 76.4±13.9 77.1±15.5 75.0±15.3 72.2±19.5 
Frequency (beats/min) 81.2±16.2 81.6±15.4 82.7±16.9 83.2±12.6 
Pulmonary capillary wedge 
pressure (mmHg) 
12.5±4.2 13.0±4.3 13.3±4.3 11.8±4.6 
Cardiac output (l/min) 5.1±1.1 5.0±0.9 5.1±1.3 5.0±0.9 
Pulmonary vascular resistance 
(dynes*sec/cm
5
) 
152.0±103.0 214.6±110.4** 151.2±114.5 207.5±112.5* 
Systemic vascular resistance 
(dynes*sec/cm
5
) 
1516.4±459.8 1478.6±535.5 1528.6±386.8 1538.6±560.4 
Angiographic findings :     
Calcification 8 (26.7%) 3 (21.4%) 8 (53.3%)** 2 (20.0%) 
Plaques 18 (60.0%) 11 (76.9%) 15 (100%)*** 7 (70.0%) 
Stenosis 15 (50.0%) 9 (64.3%) 15 (100%)*** 6 (60.0%) 
Occlusion 1 (3.3%) 0 (0%) 1 (6.7%) 0 (0%) 
Diffuse lesions 7 (23.3%) 3 (21.4%) 7 (46.7%)** 3 (30.0%) 
Aneurysm 1 (3.3%) 0 (0%) 1 (6.7%) 1 (10.0%) 
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Slow coronary flow 6 (20.0%) 4 (28.6%) 3 (20.0%) 1 (10.0%) 
Bridge 2 (6.7%) 0 (0%) 1 (6.7%) 2 (20.0%) 
Hinge 19 (63.3%) 8 (57.2%) 9 (60.0%) 8 (80.0%) 
SYNTAX score (A) 6.8±11.3 6.0±5.5 13.7±12.9*** 6.0±6.4 
Coronary flow velocity (B):     
Left anterior descending artery 29.1±14.8 25.7±13.8 25.6±11.8 19.5±9.7** 
Circumflex artery 21.4±10.6 22.5±12.7 19.7±11.3 16.3±5.0* 
Right coronary artery 17.8±14.4 18.7±10.7 17.1±11.3 13.4±9.2 
Average frame count 23.2±10.9 22.3±10.5 22.0±9.0 16.4±4.7* 
Coronary flow reserve: 2.7±1.1 2.6±1.3 2.6±1.2 1.5±0.3*** 
Table 2b: Findings of combined left and right heart catheterization in 30 patients. Abbreviations: (A) 
SYNTAX score, a validated comprehensive angiographic scoring system to describe the extent of CAD. 
(B) Coronary flow velocity, assessed by the TIMI (thrombolysis in myocardial infarction) frame count 
method, which counts the number of angiographic frames required for dye to reach standardized distal 
landmarks: for details see methods, *: p<0.05, **: p<0.01, ***: p<0.0001 compared to the rest of the 
catheterized cases using Fisher’s exact or unpaired t-test as appropriate. 
 
 Cardiac catheterisation was performed in 30 cases. In all, 20 patients were included in the 
‗‗suspected PAH‘‘, and 10 cases in the ‗‗suspected CAD‘‘ group. Among the 120 patients 
with SSc, the prevalence of PAH was 11.6% (14/120), while the prevalence of verified CAD 
and of severe CFR reduction were 12.5% (15/120) and 8.3% (10/120), respectively. Normal 
coronary vessels and pulmonary pressure, as well as preserved CFR, were found in eight 
cases. There was a considerable overlap among these groups. In all, 12 patients in the 
‗‗suspected PAH‘‘ group and 2 in the ‗‗suspected CAD‘‘ group had PAH. Coronary 
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angiography was positive in 9 cases in the ‗‗suspected PAH‘‘ group. Severely reduced CFR 
was found in seven cases in the ‗‗suspected PAH‘‘ and in three patients in the ‗‗suspected 
PAH‘‘ group (fig 1). 
 
 
Figure 1: Catheterization findings in 30 systemic sclerosis patients. Panel A shows the frequency of 
coronary artery disease (CAD) and pulmonary hypertension as indications for catheterization. Panel B 
illustrates the considerable overlap found between abnormalities of the pulmonary circulation and the 
coronary micro- and macrovasculature. Abbreviations: PAH: pulmonary arterial hypertension, CAD: 
coronary artery disease, MVD: microvascular disease 
 
Significant correlation was found between the coronary flow velocity and flow reserve values, 
indicating better CFR in patients with slower resting flow (p 0.01, r2=0.24). Of the 15 
patients with coronary lesions detected by morphological and functional assessment, 8 
underwent revascularisation (1 bypass grafting, 7 percutaneous coronary stent implantations). 
These procedures resulted in improvement in the patients‘ physical activity (Figure 2). 
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Figure 2: Effect of coronary revascularization on physical competence and echocardiographic parameters. 
Dots represent percentage relative to initial mean values. Open circles show baseline state, while grey 
circles refer to 30-day evaluation after coronary intervention. Revascularization improved walking 
distance in 6-minute walk test (6-MWT, p<0.001) and decreased Borg dyspnoea index in 8 SSc patients 
(p<0.05).  Ejection fraction (EF) and E/A values representing systolic and diastolic left ventricular 
function did not show significant difference between time points.  
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4 Investigation of coronary microcirculatory parameters and 
mechanisms of coronary microvascular dysfunction in SSc 
4.1 Patients and methods 
Diffuse and limited subset of SSc cases were diagnosed by the commonly used criteria
1
. The 
trial protocol was approved by the Medical Research Council Scientific and Ethical 
Committee (330/PI/2007) and patients provided informed consent before the study. Each 
patient underwent a baseline physical examination. Lung involvement was investigated by 
using chest X-ray, pulmonary function tests, and high resolution computed tomography if 
interstitial lung disease was suspected. Duration of Raynaud‘s phenomenon (RP) at the time 
of the study entry was evaluated by clinical interview, while duration of SSc was determined 
from the time of the onset of the first SSc-related non-Raynaud symptom. Patients with 
decreased systolic function (ejection fraction <30% on echocardiography), with known severe 
valvular disease or with severe lung fibrosis (forced vital capacity <50%) were excluded from 
further investigations. Cardiac catheterization was initiated in the presence of abnormalities, 
which were suggestive of pulmonary arterial hypertension (PAH) or of coronary artery 
disease. Detailed criteria for catheterization are published elsewhere
70
. 
Briefly, criteria for the ‗suspected PAH‘ included signs of right ventricular involvement on 
echocardiography (tricuspid insufficiency diagnosed by flow velocity over 3 m/s, or 
consistent with 2.5-3m/s in the presence of unexplained dyspnoea, signs of right ventricular 
hypertrophy/dilatation, or right ventricular D sign) and effort related dyspnoea with 
disproportional decrease of CO diffusion capacity (DLCO) compared to the forced vital 
capacity (FVC/DLCO >1.8). Patients were included in the ‗suspected CAD‘ group if they 
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reported recent deterioration in physical activity, evolving effort dyspnoea, or chest pain, or 
fulfilled the criteria of the New York Heart Association functional classes III-IV, or if their 6-
minute walking distance was <380m, but it did not fulfilled the criteria for PAH
14, 70
. 
Coronary angiographic findings and coronary flow reserve data of the first ten consecutive 
patients were included in our previous publication
70
. Subsequent seven SSc patients were 
enrolled according to the same protocol for investigation of the myocardial resistance levels. 
The Ca-antagonist therapy was stopped for more than twenty four hours before cardiac 
catheterization. Right heart catheterization (RHC) and coronary angiography, supplemented 
with thermodilution CFR assessment were performed at the same time. Intracoronary 
pressure-wire measurements of 17 patients with intermediate coronary lesions were used as 
control. 
4.1.1 Echocardiography and Right Heart Catheterization 
The methods of Echocardiography and Right Heart Catheterization applied during the study 
have been explained in details in chapter 3.1.1. and 3.1.2. 
4.1.2 Coronary angiography 
The coronary arteriography was performed as described in chapter 3.1.3. 
IMR was calculated as a product of mean transit time and Pd, in hyperemia and at rest. 
(Figure 3) 
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Figure 3: Calculation of hemodynamic parameters. During the pressure-wire measurements aortic 
pressure at the coronary orifice (Pa), distal coronary pressure at the tip of the wire (Pd) and mean transit 
time of 3 ml room temperature saline (Tm) were measured at basal conditions and during hyperemia 
(subscript ‘bas’ and ‘hyp’, respectively) A: Fractional flow reserve (FFR) was calculated as a Pd/Pa ratio 
during hyperemia. B: coronary flow reserve (CFR) was calculated from the ratio of the mean transit times 
in hyperemia and at rest. C: Index of myocardial resistance (IMR) was calculated as a product of mean 
transit time and Pd, in hyperemia and at rest. 
 
4.1.3 Statistical analysis 
Continuous variables are presented as mean ± SD. All analyses were performed with SPSS 
Software (version 16.0, SPSS Inc., Chicago, IL, USA). In group comparison unpaired t-test, 
chi-square test or Fisher‘s exact test were used as appropriate. Pearson r test was used to 
examine correlations. 
4.2 Results 
Demographics, treatment and echocardiographic characteristics of the included patients are 
depicted in Table 3, while patient characteristics and pulmonary findings of the systemic 
sclerosis patients are summarized in Table 4a, b. 
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 SSc patients 
(n=17) 
Controls 
(n=17) 
Age (years) 59.9±12.0 58.3±7.5 
Gender (male:female) 5:12 9:8 
Hypertension 9(52.9%) 13 (65.0%) 
Diabetes mellitus 0 (0%) 5 (27.8%)* 
Hypercholesterolemia 3 (17.6%) 7(41.1%) 
BMI (kg/m
2
) 25.2±5.3 27.6±3.8 
Smoker 0 (0%) 1 (5.9%) 
Treatment:   
Ca-channel blockers 13 (76.5%) 4 (23.5%)** 
Nitrates 3 (17.6%) 6 (35.5%) 
ß-blockers 5 (29.4%) 9 (52.9%) 
ACE inhibitors 4 (23.5%) 7 (41.2%) 
Statins 2 (11.8%) 9 (52.9%)* 
Pentoxyphilline 17 (100.0%) 1 (5.9%)** 
Cyclophosphamide† 6 (35.5%) 0 (0.0%)** 
Low dose corticosteroid† 9 (52.9%) 0 (0.0%)** 
Echocardiography:   
Ejection fraction 58.88±6.32 55.55±2.82 
Calculated RV systolic pressure 
(mmHg) 
34.43±7.10 35.33±6.00 
E/A 1.01±0.39 0.75±0.23 
Table 3: Data are presented as mean ± SD or number of patients (percent). Abbreviations: BMI: body 
mass index, ACE: angiotensin converting enzyme, HRCT: high resolution computer tomography, RV: 
right ventricle, E/A: ratio of the early (E) and late (A) velocities of the transmitral flow,*: p<0.05 
**p<0.001 unpaired t test or Fisher’s exact test as appropriate. † Cyclophosphamide intake was encoded 
when cyclophosphamide treatment for at least 12 months, with an average dose of 1000 mg/month, was 
recorded in the patient’s medical history. Steroid intake was marked when low or medium dose 
corticosteroid treatment was recorded in the patient’s medical history for at least 12 months. 
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SSc patients 
(n=17) 
LcSSc:DcSSc 8:9 
Disease duration (years) 9.6±8.3 
Follow-up (months) 48.0±52.0 
SSc Disease Activity Index  3.3±2.1 
Medsger Severity Scale 8.2±3.2 
HAQ-DI 0.8±0.6 
ANA screen 16 (94.1%) 
ACA 3 (17.6%) 
Scl-70 6 (35.3%) 
Clinical manifestations, case history:  
Raynaud‘s phenomenon 17 (100.0%) 
Subcutaneous calcinosis 2 (11.8%) 
Myositis 3 (17.6%) 
Modified Rodnan skin score 8.5±10.0 
Abnormal Shirmer‗s test 5 (29.4%) 
Pericarditis 0 (0%) 
Renal involvement 1 (5.9%) 
Esophageal involvement 11 (64.7%) 
Table 4a: Data are presented as mean ± SD or number of patients (percent). Abbreviations: lcSSc: limited 
cutaneous systemic sclerosis, dcSSC: diffuse cutaneous systemic sclerosis, SSc: systemic sclerosis, HAQ-
DI: Health assessment questionnaire disability index, ANA: antinuclear antibody on human HEp-2 cells, 
ACA anti-centromer antibody. 
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SSc patients 
(n=17) 
Lung function test:  
FVC 98.6±16.6 
DLCO 56.3±16.4 
DLCO/VA 68.6±16.6 
HRCT:  
Basal fibrosis 10 (58.8%) 
Diffuse fibrosis 5 (29.4%) 
Honeycombing 2 (11.8%) 
Right heart catheterization:  
Pulmonary artery mean pressure (mmHg) 23.6±10.6 
Pulmonary capillary wedge pressure (mmHg) 12.3±6.0 
Pulmonary arterial resistance (dynes*sec/cm
5
) 256.9±272.6 
Systemic vascular resistance (dynes*sec/cm
5
) 1600.7±431.9 
Cardiac output (l/min) 5.1±1.4 
Lung function test:  
FVC 98.6±16.6 
DLCO 56.3±16.4 
DLCO/VA 68.6±16.6 
HRCT:  
Basal fibrosis 10 (58.8%) 
Diffuse fibrosis 5 (29.4%) 
Honeycombing 2 (11.8%) 
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Right heart catheterization:  
Pulmonary artery mean pressure (mmHg) 23.6±10.6 
Pulmonary capillary wedge pressure (mmHg) 12.3±6.0 
Pulmonary arterial resistance (dynes*sec/cm
5
) 256.9±272.6 
Systemic vascular resistance (dynes*sec/cm
5
) 1600.7±431.9 
Cardiac output (l/min) 5.1±1.4 
Table 4b: Data are presented as mean ± SD or number of patients (percent). Abbreviations: SSc: systemic 
sclerosis, FVC: forced vital capacity, DLCO: diffusing capacity for carbon monoxide, DLCO/VA: carbon 
monoxide diffusing capacity adjusted for alveolar volume 
 
The control group was matched for gender and age. Cardiovascular risk profile was similar 
except for the more frequent diabetes in control group. All SSc patients but none of the 
controls reported the presence of Raynaud‘s phenomenon (RP). Regarding therapy, the 
patients in the control group used significantly less calcium channel blockers, 
pentoxyphylline, cyclophosphamide and corticosteroids. Baseline hemodynamic data were 
similar between the two groups. The severity of coronary atherosclerosis as expressed by the 
QCA and SYNTAX scores did not differ significantly (P=0.830, and P=0.821, respectively). 
The SSc patient group and the control group were similar with regard to TFC, FFR and CFR 
(P=0.604, P=0.651 and P=0.117, respectively, Table 5).  
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SSc patients 
(n=17) 
Controls 
(n=17) 
Basic hemodynamic data:   
Systolic pressure (mmHg) 137.1±25.9 148.3±32.6 
Diastolic pressure (mmHg) 77.9±15.6 84.3±16.2 
Frequency (beats/min) 75.9±13.1 81.9±19.7 
Angiographic findings:   
Calcification 6 (35.6%) 4(22.2%) 
Plaques 12 (70.6%) 14 (77.8%) 
Occlusion 1 (5.9%) 0 (0%) 
Diffuse sclerosis 4 (23.5%) 5 (27.8%) 
Aneurysm 1 (5.9%) 0 (0%) 
Bridge 2 (11.8%) 1 (5.6%) 
SYNTAX score  10.7±10.7 9.9±8.4 
Coronary flow velocity:   
Left anterior descending artery 28.4±16.8 24.6±9.5 
Circumflex artery 23.9±14.2 23.0±9.0 
45 
 
Right coronary artery 18.8±16.4 19.7±9.9 
Average frame count 23.7±13.2 21.7±7.3 
Intracoronary pressure measurement:   
Coronary flow reserve (CFR) 3.1±1.7 2.3±1.0 
Fractional flow reserve (FFR) 0.9±0.1 0.9±0.1 
Quantitative Coronary Angiography stenosis 
(QCA) (%) 
48.4±15.1 49.3±8.2 
Index of myocardial resistance:   
At rest (IMRbas) 67.7±40.4 51.1±33.0 
At hyperemia (IMRhyp) 19.0±7.5 18.1±8.4 
Table 5: Data are presented as mean ± SD or number of patients (percent). Abbreviations: SYNTAX 
score: a validated comprehensive angiographic scoring system to describe the extent of coronary artery 
disease. (IMRbas): Basal myocardial resistance. (IMRhyp): Myocardial resistance at maximal vasodilatation  
 
The IMRbas was not significantly higher in the SSc group (P=0.207), and in response to 
maximal vasodilatation there was no significant difference between SSc patients and controls 
(P=0.731) (Fig.4). 
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Figure 4: In systemic sclerosis (SSc) patients the myocardial resistance at maximal vasodilatation (IMRhyp) 
was not significantly different from controls (p=0.99). The difference of the magnitude of the response to 
vasodilatation (i.e. the coronary flow reserve) is dominated by the differences in the resting resistance 
(IMRbas) i.e. in the vascular tone. 
 
 CFR values lower than 2 were detected in six SSc patients. These patients had higher basal 
coronary flow velocities than SSc patients with normal CFR (10.63±5.1 vs. 27.53±14.8 
p<0.05) (Figure 5). 
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Figure 5: TIMI frame count (TFC) of SSc patients with normal CFR were significantly higher, than in 
SSc patients with decreased CFR, which indicate accelerated coronary flow among patients with 
restricted coronary reserve. 
 
We found a trend for lower IMRbas values in these patients (43.8±23.6 vs. 80.7±42.5, P=0.07). 
IMRhyp differed significantly neither from the SSc patients with normal CFR nor from the 
control group (21.68±6.61, 17.23±7.83 and 17.80±8.17, respectively, P=0.292 and P=0.308). 
The IMRbas correlated to the coronary flow velocity (R=0.56, p<0.05) (Figure 6). 
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Figure 6: The baseline myocardial resistance shows significant linear correlation with the coronary flow 
velocity – assessed by the TFC. (RPearson=0.56, p<0.02) 
 
There was no significant difference between limited cutan (lcSSc) and diffuse form (dSSc) of 
SSc as regards CFR, IMRbas and IMRhyp results. Clinical complaints showed neither relation 
to these parameters (data not shown). Mean transit time values during the baseline conditions 
in SSc patients were 0.75±0.39, 0.72±0.50, and 0.67±0.41 sec, in the controls 0.56±0.37, 
0.55±0.36, 0.51±0.41 sec in baseline and 0.27±0.11, 0.27±0.14, 0.22±0.10 versus 0.25±0.14, 
0.22±0.12, and 0.23±0.12 sec in hyperemia. No trend for deceleration was found (Figure 7). 
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Figure 7: Mean transit time values in baseline and in hyperemia. After injection of room-temperature 
saline we observed longer transit times among SSc patients, however, this difference was not significant. 
In response to the repeated injections, lack of deceleration of the coronary artery flow suggests the 
absence of coronary Raynaud’s phenomenon. 
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5 Novel findings of the thesis 
Our studies demonstrated that coronary artery disease may mimic, and can appear in 
combination with PAH in patients with SSc. Patients with SSc with reduced physical capacity 
and exertional dyspnoea showed a considerable overlap between PAH and CAD. We found 
that among patients who showed signs of PAH by non-invasive investigations, the prevalence 
of CAD and PAH was comparable.  
We found that, coronary revascularisation successfully eases symptoms and improves 
physical capacity. Therefore, screening for the presence of coronary artery disease by invasive 
methods seems to be indicated in symptomatic cases of SSc. 
In our cohort coronary flow velocity showed inverse relation to the CFR, indicating that 
coronary flow deceleration is reversible in patients with SSc.  
The index of myocardium resistance in hyperemia (IMRhyp) is not increased in SSc patients 
compared to controls having no significant epicardial coronary artery stenosis suggesting that 
there is no irreversible damage at the level of the coronary arterioles in SSc. 
In SSc patients with reduced CFR we demonstrated the decrease of the basal IMR, which 
suggests together with accelerated flow velocity the presence of a compensatory mechanism 
to maintain myocardial perfusion at rest already.  
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6 Discussion 
This study demonstrated that coronary artery disease may mimic, and can appear in 
combination with PAH in patients with SSc. Patients with SSc with reduced physical capacity 
and exertional dyspnoea showed a considerable overlap between PAH and CAD. The 
incidence of PAH in our study was similar to that observed previously
14, 71
. Intriguingly, in 
patients who showed signs of PAH by non-invasive investigations, the prevalence of CAD 
and PAH was comparable. Patients with suspected CAD also showed similar overlap, 
although this was less prominent. ‗‗Pure‘‘ PAH without coronary disease was a rather rare 
finding in our cohort, only affecting 10% of the cases. These findings suggest that the current 
screening methods are not ideal for distinguishing CAD and PAH in patients with SSc. 
Thus a more invasive approach, such as conventional or CT coronary angiography, may be 
necessary to properly characterise heart involvement in SSc. Moderate pulmonary fibrosis 
was equally distributed among the groups, supporting recent studies indicating that pulmonary 
vascular and interstitial involvement progresses independently
72
. Incorporating the 
examination of the coronaries into the catheterisation protocol resulted in a reduction of the 
number of negative examinations. Still, a reasonable explanation for findings suggestive of 
cardiopulmonary involvement was lacking in a remarkably high number of patients (8/30) 
with normal RHC values, normal coronaries and without severe pulmonary fibrosis. These 
data indicate that a more complex approach should be developed for the evaluation of 
cardiopulmonary involvement in SSc. Angina in scleroderma is a weak predictor of CAD, as 
patients with SSc with chest pain are half as likely to have CAD compared to the general 
population. In a retrospective analysis of 172 SSc cases, 47% and 50% standard prevalence 
ratios were found for CAD in the typical and atypical angina group, while in the non-anginal 
or breathlessness group the ratio was 93%
73
. Compared to our findings, the overall prevalence 
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of CAD was lower in this study. The main difference between the two studies was the 
selection of patients for coronary angiography, as our selection criteria covered a wider 
patient group. Indications for angiography may influence the incidence of CAD, and the more 
extensively coronary angiography is performed, the larger number of affected patients may be 
found
74
. In this study the coronary flow velocity was quantified by using the TIMI frame 
count (TFC). Slow coronary flow has been hypothesised to be the result of microvascular loss 
and characterised by an increased TFC, reduced CFR and microvascular angina. Restriction 
of coronary adaptation in patients with SSc is attributed to involvement of microvasculature 
and considered to be a characteristic of primary myocardial disease
21, 29, 30
. We found that this 
feature does not apply uniformly to all patients. In our cohort, none of the patients had 
abnormally high TFC, but interestingly, velocity showed inverse relation to the CFR, 
indicating that coronary flow deceleration is reversible in patients with SSc. Alternatively, the 
use of vasodilator agents may improve the myocardial perfusion in those patients in whom 
coronary flow reserve is maintained. We conclude that CAD can be found in a considerable 
proportion of patients with SSc and overlaps substantially with PAH. In selected patients, 
coronary revascularisation successfully eases symptoms and improves physical capacity. 
Therefore, screening for the presence of coronary artery disease by invasive methods seems to 
be indicated in symptomatic cases of SSc. 
To our knowledge our work was the first study which assessed the myocardial resistance in 
SSc patients by intracoronary pressure-wire measurement. The main finding of our 
investigation is that the index of myocardium resistance in hyperemia (IMRhyp) is not 
increased in SSc patients compared to controls having no significant epicardial coronary 
artery stenosis suggesting that there is no irreversible damage at the level of the coronary 
arterioles in SSc. Coronary arterioles are responsible for the distribution of the myocardial 
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blood flow. Their function is subject to delicate regulation by different signals of local 
ischemia. The cornerstone of myocardial vascular resistance is the active tone of the 
arterioles. It has been hypothesized on the basis of recent studies that in SSc patients the loss 
of the arterioles and consequent reduction of the arteriolar bed‘s cross-section result in an 
increased hyperemic resistance
20, 75
. This concept however, was not confirmed by our results. 
The next step of the regulation is the level of microcirculation. Capillary field is exceptionally 
dense in the heart providing one capillary to one myocyte
76
. Capillaries are not uniformly 
patent because the precapillary sphincters regulate flow according to demand.  
In some conditions, i.e. left ventricular hypertrophy, ischaemic heart disease and diabetes 
mellitus, the impaired microcirculation with increased resistance and elevated resting blood 
flow is known. This process inspired to insure myocardial oxygen demand, resulting in 
reduced CFR. 
In our study, in SSc patients with reduced CFR we demonstrated the decrease of the IMRbas, 
which suggests together with accelerated flow velocity the presence of a compensatory 
mechanism to maintain myocardial perfusion at rest already. This process may cause 
exhaustion of the adaptive capacity and results in ischemia at a lower threshold. Consistently 
with other studies that consequently demonstrated myocardial perfusion defects in SSc we 
hypothesize that these ischemic signals arise from the microcirculatory bed distally from the 
level of resistance arterioles. 
Thus loss of capillaries would not influence the hyperemic resistance, yet may lead to 
ischemia of the contractile elements. We found that SSc patients with reduced CFR exhibited 
decreased basal resistance. At the presence of coronary stenosis the reduction of the basal tone 
at rest is a compensatory mechanism that intends to maintain the myocardial perfusion despite 
54 
 
the decreased distal coronary perfusion pressure
50, 54
. In our SSc cohort FFR values were 
normal; supporting the absence of hemodynamically significant stenosis, consequently 
compensation for the diminished distal coronary pressure can be excluded. However, this fact 
mentioned above together with the signs of accelerated flow in rest in patients with low CFR 
suggests that decrease of resting resistance may be a consequence of compensatory 
mechanisms alerted by ischemic signals from the myocardium.  
Previous studies could only estimate the coronary flow parameters in SSc patients. Although 
Nitenberg et al. have investigated the coronary blood flow and myocardial resistance levels 
invasively
20
, the coronary perfusion pressure was calculated and the coronary blood flow was 
evaluated using thermodilution measurements in the coronary sinus. Our data are based on 
direct invasive measurements of intracoronary pressures, which provide more accurate 
pressure values enhancing the strength of our findings. Without direct measurement of Pd, a 
diffuse but hemodynamically significant stenosis cannot be excluded.  
Several studies have attempted to characterize non-invasively the coronary vasoreactivity in 
SSc patients
28-30
. Measurement of the diastolic coronary flow obtained by transthoracic 
echocardiography initially has been reported to exhibit suboptimal feasibility, which can be 
improved by using contrast augmentation of the Doppler signal and second harmonic 
technology (CFRecho)
31-33
. 
Sulli et al. found significantly lower CFRecho values among patients with diffuse SSc than in 
subjects suffering from the limited form of the disease. In our cohort such a difference has not 
been found. Furthermore, CFRecho values in SSc differed significantly from healthy controls 
while we found similar CFR values when compared to the patients referred to cardiac 
catheterization in order to exclude CAD
30
.  
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Montisci et al found that the peak diastolic velocity was significantly decreased in the left 
anterior descending coronary artery in basal conditions and the CFRecho measured during 
adenosine infusion increased significantly after single intravenous L-propionylcarnitine 
application. It may be interpreted as the ―antiendothelin‖ effect of L-propionylcarnitine for 
microvascular tone and this agent could cause improved sensitivity for adenosine infusion
31
.  
D‘Andrea et al conclude that endothelial dysfunction in SSc patients was not confined to 
coronary microvessels, but also extends to peripheral arteries
28
. This concept is in line with 
recent observations that found impairment of endothelium dependent vasodilatation in SSc, 
while endothelium independent vasodilatation is preserved.
77
 Similar results were found 
earlier by Andersen et al
34
. Limitation of these studies is the lack of strict pressure 
measurement allowing only indirect determination of the coronary flow. Further limitation is 
the lack of information about the coronary anatomy. Coronary heart disease in forms of 
coronary artery sclerosis and microvascular disease can be found frequently in combination in 
symptomatic SSc patients
70
. Furthermore, clinical presentation of atherosclerosis is atypical in 
this patient group and coronary abnormalities may be found among symptom free patients
73, 
74
. 
Studies investigating the myocardial perfusion in SSc have found irreversible as well as 
reversible perfusion defects. These have no coronary artery anatomy related distribution and 
calcium channel blockers, dipyridamole or captopril treatment resulted in their partial 
reversibility
25, 29, 30, 78
. These findings altogether support the idea that abnormal vasoreactivity 
causing episodic focal ischemia is associated with the myocardial fibrosis related structural 
myocardial disease
75
. 
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Cardiac magnetic resonance studies demonstrated that the presence of areas with late-
enhancement corresponding to the fibrotic areas earlier found by autopsy studies are common 
finding
15, 16, 79, 80
. Distribution of the fibrosis did not show a direct relationship to the coronary 
anatomy, however, coronary artery disease is a frequent finding in SSc patients presenting 
with cardiac symptoms
70
. In a recent study fibrosis was found in 66% of SSc cases. These 
lesions were found more frequently in cases with long history of RP.  There was no different 
incidence found between diffuse and limited cutan forms of SSc
80
. Allanore et al. 
demonstrated that the myocardial perfusion index can improve after administration of 
endothelin receptor antagonist bosentan
36
. This finding confirms our hypothesis that the 
improvement of endothelial function which is mainly represented by capillary system can 
repair the myocardial perfusion. 
In our study we did not find any correlation with history of the RP the basal resistance 
(IMRbas) of SSc patients did not differ significantly from the controls. The concept that 
Raynaud-like mechanisms may be involved in the evolution of the scleroderma specific 
internal organ damage is a tempting hypothesis. Mukerjee et al. investigated the effect of 
central and peripheral cold challenges in 21 SSc patients with PAH. They did not verify 
significant changes in hemodynamic parameters and in the level of vasoactive peptides after a 
two- minute long hand immersion into cold water or after administration of 4C
o
 saline into the 
right atrium, so they excluded that cold provocation could alter the pulmonary circulation
81
. 
Theoretically, the hemodynamic changes caused by low temperature in the heart are even less 
probable. Our results strengthen this statement since the injection of room temperature saline 
into the coronaries did not provoke angina or spasm and we did not find any increase of the 
transit times. The IMRbas was not elevated in SSc patients despite the stress situation, and the 
cool temperature of the cathlab. 
57 
 
Our study has certain limitations. The gender distribution was different in the two groups 
although this difference was not statistically significant probably due to the small sample size. 
Considering the cardiovascular risk factors, the incidence of the hypercholesterolemia was 
significantly higher in the control group; both of them may influence the vasoreactivity of the 
coronary arteries. We did not find significant difference in the IMRbas between the CFR 2 and 
CFR 2 SSc groups. One possible explanation can be the high standard deviation of those 
values. Furthermore in our current study we assessed neither the myocardial metabolisms nor 
the myocardial perfusion.  
In conclusion, reduced CFR can be considered as a sign of SScMI. Our observations support 
that in SSc the reduction of the CFR is mainly attributable to a decrease of the basal 
myocardial resistance i.e. with lower arteriolar tone and with an accelerated coronary flow 
velocity. These findings suggest a sort of compensatory state. Vasodilatory treatment may 
cause further decrease in the tone of the arterioles, which may be primarily effective among 
patients with retained CFR. Further studies are needed to characterize the mode of action of 
these vasodilatory drugs in SSc. 
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